Biocrystal introduces breakthrough in cell culture technology
OptiCell Device Revolutionizes The Cell Culture Process
BioCrystal, Ltd., a central Ohio biotechnology company, today introduced OptiCell, a groundbreaking system of products that will revolutionize cell culture technology in biological and health science laboratories around the world.
The commercialization of OptiCell's Total Cell Management Tool marks the first advancement in cell culture in more than 50 years. While traditional cell culture products like the Petri dish and flask have remained virtually unchanged since the 1940s, the innovative design of OptiCell will have a dramatic impact on drug discovery and proteomics because it eliminates the bottleneck of cell culture and allows for laboratory automation.
Cell culture is an important step in the development and production of products that we often take for granted in our everyday lives. Laboratory-grown cells are the basis for understanding elementary biological and disease processes. They provide experimental systems for mapping human and other extensively studied genomes can be used in development of drugs, vaccines and other products from cosmetics to pesticides, and can replace animals in certain kinds of testing. Cell culture will also be a key component in the future for proteomics and human stem cell research.
OptiCell is a sterile cell environment sealed between two optically clear gas-permeable growth surfaces in a standard microtiter plate-sized frame; self-sealing ports provide easy aseptic access to the interior and its contents.
OptiCell accommodates a full range of cell culture activities from cell growth and magnetic separation to staining, microscopy, transfection, shipping and drug discovery.
OptiCell reduces cost, minimizes the risk of contamination, saves laboratory and incubator space, decreases solid waste and allows for optimal use of research time. By streamlining traditional cell culture processes, OptiCell will revolutionize performance and productivity in basic life science research, drug and vaccine production, cellular therapy, proteomics, pharmacogenomics, and drug discovery.
BioCrystal, Ltd. gratefully acknowledges the Ohio Department of Development (ODOD), who has provided assistance through economic incentive programs created to encourage the development of technology resources in the state of Ohio.
BioCrystal, Ltd. is developing novel products and services for applications in life science research and clinical medicine, including immuno-therapeutic compounds and procedures for the diagnosis and treatment of cancer. BioCrystal, Ltd. will use its IP portfolio to generate revenues from a combination of direct sales of manufactured products, license-associated royalty income and the sale of technology, or access rights to same, for commercialization by others.
Source: BioCrystal, Ltd.
Subscribe to our free e-mail newsletter.
Click for a free Buyer's Guide listing.